Vitamin D as a clinical biomarker in multiple sclerosis

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 3, 2013, Pages 231-242

  Carlson, Noel G ^a,b,c,d   Rose, John W ^a,b,c,d  

^a VASLCHCS   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Epstein Barr nuclear antigens 3; Epstein Barr virus; Experimental autoimmune encephalomyelitis and magnetic resonance imaging; Multiple sclerosis; Vitamin D; Vitamin D receptor

Indexed keywords

25 HYDROXYVITAMIN D; CALPAIN 2; CASPASE 8; CELL NUCLEUS ANTIGEN; COLECALCIFEROL; FISH OIL; GLATIRAMER; GLIAL FIBRILLARY ACIDIC PROTEIN; HLA DRB1 ANTIGEN; INITIATION FACTOR 2ALPHA; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 17; VITAMIN D; VITAMIN D BINDING PROTEIN; VITAMIN D RECEPTOR; BIOLOGICAL MARKER;

ALLERGIC ENCEPHALOMYELITIS; ANTIBODY TITER; AUTOIMMUNITY; B LYMPHOBLAST; CALCIUM INTAKE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA SEQUENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GENE PRODUCT; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; IMMUNOPRECIPITATION; LOW DRUG DOSE; MOLECULAR INTERACTION; MORBIDITY; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; RISK FACTOR; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; METABOLISM;

BIOLOGICAL MARKERS; HUMANS; MULTIPLE SCLEROSIS; VITAMIN D;

EID: 84876883207     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.772978     Document Type: Review

References (90)

1. Handunnetthi L, Ramagopalan SV. UV radiation, vitamin D, and multiple sclerosis. Proc Natl Acad Sci USA 2010;107(33):E130; author reply E131
2. Orton SM, Wald L, Confavreux C, et al. Association of UV radiation with multiple sclerosis prevalence and sex ratio in France. Neurology 2011;76(5):425-31
3. Ramagopalan SV, Handel AE, Giovannoni G, et al. Relationship of UV exposure to prevalence of multiple sclerosis in England. Neurology 2011;76(16):1410-14
4. Antico A, Tampoia M, Tozzoli R, et al. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 2012;12(2):127-36
5. Baarnhielm M, Hedstrom AK, Kockum I, et al. Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen-DRB1*15. Eur J Neurol 2012;19(7):955-62
6. Disanto G, Chaplin G, Morahan JM, et al. Month of birth, vitamin D and risk of immune mediated disease: a case control study. BMC Med 2012;10(1):69
7. Disanto G, Morahan JM, Ramagopalan SV. Multiple sclerosis: risk factors and their interactions. CNS Neurol Disord Drug Targets 2012;11(5):545-55
8. Munger KL, Chitnis T, Frazier AL, et al. Dietary intake of vitamin D during adolescence and risk of multiple sclerosis. J Neurol 2011;258(3):479-85
9. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296(23):2832-8
10. Kampman MT, Steffensen LH, Mellgren SI, et al. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 2012;18(8):1144-51
11. Shaygannejad V, Janghorbani M, Ashtari F, et al. Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Mult Scler Int 2012;2012:452541
12. Loken-Amsrud KI, Holmoy T, Bakke SJ, et al. Vitamin D and disease activity in multiple sclerosis before and during interferon-beta treatment. Neurology 2012;79(3):267-73
13. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72(2):234-40
14. Runia TF, Hop WC, de Rijke YB, et al. Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology 2012;79(3):261-6
15. Stewart N, Simpson S Jr, van der Mei I, et al. Interferon-beta and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012;79(3):254-60
16. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010;9(6):599-612
17. Simon KC, Munger KL, Ascherio A. Vitamin D and multiple sclerosis: epidemiology, immunology, and genetics. Curr Opin Neurol 2012;25(3):246-51
18. Haussler MR, Whitfield GK, Kaneko I, et al. Molecular Mechanisms of Vitamin D Action. Calcif Tissue Int 2012;92(2):77-98
19. Handel AE, Disanto G, Jarvis L, et al. Seasonality of admissions with multiple sclerosis in Scotland. Eur J Neurol 2011;18(8):1109-11
20. Gelfand JM, Cree BA, McElroy J, et al. Vitamin D in African Americans with multiple sclerosis. Neurology 2011;76(21):1824-30
21. Handel AE, Gillie O, Ramagopalan SV. Inequities in advice on vitamin D? QJM 2011;104(6):547-9
22. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol 2009;23(6):789-95
23. Ramagopalan SV, Dyment DA, Cader MZ, et al. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011;70(6):881-6
24. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010;20(10):1352-60
25. Disanto G, Sandve GK, Berlanga-Taylor AJ, et al. Vitamin D receptor binding, chromatin states and association with multiple sclerosis. Hum Mol Genet 2012;21(16):3575-86
26. Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci U S A 2008;105(35):13069-74
27. Cocco E, Meloni A, Murru MR, et al. Vitamin D responsive elements within the HLA-DRB1 promoter region in Sardinian multiple sclerosis associated alleles. PLoS ONE 2012;7(7):e41678
28. Nolan D, Castley A, Tschochner M, et al. Contributions of vitamin D response elements and HLA promoters to multiple sclerosis risk. Neurology 2012;79(6):538-46
29. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996;93(15):7861-4
30. Joshi S, Pantalena LC, Liu XK, et al. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011;31(17):3653-69
31. Spach KM, Pedersen LB, Nashold FE, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics 2004;18(2):141-51
32. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha, 25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys 2002;408(2):200-4
33. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin. Nat Immunol 2005;6(11):1133-41
34. Spach KM, Nashold FE, Dittel BN, et al. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006;177(9):6030-7
35. Wang Y, Marling SJ, Zhu JG, et al. Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor. Proc Natl Acad Sci U S A 2012;109(22):8501-4
36. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989;58(2):227-9
37. Chen Y, Kong J, Sun T, et al. 1,25-Dihydroxyvitamin D(3) suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kappaB activation. Arch Biochem Biophys 2011;507(2):241-7
38. Giarratana N, Penna G, Amuchastegui S, et al. A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 2004;173(4):2280-7
39. Moreno J, Krishnan AV, Peehl DM, et al. Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway. Anticancer Res 2006;26(4A):2525-30
40. Miyamoto K, Miyake S, Mizuno M, et al. Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. Brain 2006;129(Pt 8):1984-92
41. Muthian G, Raikwar HP, Johnson C, et al. COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis. J Clin Immunol 2006;26(1):73-85
42. Carlson NG, Rojas MA, Redd JW, et al. Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death. J Neuroinflammation 2010;7:25
43. Carlson NG, Hill KE, Tsunoda I, et al. The pathologic role for COX-2 in apoptotic oligodendrocytes in virus induced demyelinating disease: implications for multiple sclerosis. J Neuroimmunol 2006;174(1-2):21-31
44. Palumbo S, Toscano CD, Parente L, et al. The cyclooxygenase-2 pathway via the PGE(2) EP2 receptor contributes to oligodendrocytes apoptosis in cuprizone-induced demyelination. J Neurochem 2012;121(3):418-27
45. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 2009;9(5):575-81
46. Xie L, Li XK, Takahara S. Curcumin has bright prospects for the treatment of multiple sclerosis. Int Immunopharmacol 2011;11(3):323-30
47. Torkildsen O, Wergeland S, Bakke S, et al. omega-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial. Arch Neurol 2012;69(8):1044-51
48. Allen AC, Kelly S, Basdeo SA, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler 2012;18(12):1797-800
49. Effraimidis G, Badenhoop K, Tijssen JG, et al. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. Eur J Endocrinol 2012;167(1):43-8
50. Munger KL, Levin LI, O'Reilly EJ, et al. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 2011;17(10):1185-93
51. Decard BF, von Ahsen N, Grunwald T, et al. Low vitamin D and elevated immunoreactivity against Epstein-Barr virus before first clinical manifestation of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83(12):1170-3
52. Disanto G, Morahan JM, Barnett MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78(11):823-32
53. Lossius A, Vartdal F, Holmoy T. Vitamin D sensitive EBNA-1 specific T cells in the cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2011;240-241:87-96
54. Disanto G, Meier U, Giovannoni G, et al. Vitamin D: a link between Epstein-Barr virus and multiple sclerosis development? Expert Rev Neurother 2011;11(9):1221-4
55. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61(4):288-99
56. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 2010;9(7):727-39
57. Yenamandra SP, Hellman U, Kempkes B, et al. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell Mol Life Sci 2010;67(24):4249-56
58. Disanto G, Handel AE, Ramagopalan SV. Estrogen-vitamin D interaction in multiple sclerosis. Fertil Steril 2011;95(1):e3; author reply e4
59. Holmqvist P, Hammar M, Landtblom AM, et al. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril 2010;94(7):2835-7
60. Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. J Neurol Sci 2009;286(1-2):99-103
61. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009;175:239-51
62. Barrera D, Avila E, Hernandez G, et al. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J Steroid Biochem Mol Biol 2007;103(3-5):529-32
63. Krishnan AV, Swami S, Peng L, et al. Tissue-selective regulation of aromatase expression by calcitriol: implications for breast cancer therapy. Endocrinology 2010;151(1):32-42
64. Yague JG, Garcia-Segura LM, Azcoitia I. Selective transcriptional regulation of aromatase gene by vitamin D, dexamethasone, and mifepristone in human glioma cells. Endocrine 2009;35(2):252-61
65. Cheema C, Grant BF, Marcus R. Effects of estrogen on circulating "free" and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest 1989;83(2):537-42
66. Nashold FE, Spach KM, Spanier JA, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol 2009;183(6):3672-81
67. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67(5):618-24
68. Pierrot-Deseilligny C, Rivaud-Pechoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord 2012;5(4):187-98
69. Mowry EM, Waubant E. Pediatric multiple sclerosis. Continuum (Minneap Minn) 2010;16(5 Multiple Sclerosis):181-92
70. Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ 2010;340:c1640
71. Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ 2005;330(7483):120
72. Manson JE, Bassuk SS, Lee IM, et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012;33(1):159-71
73. Dorr J, Ohlraun S, Skarabis H, et al. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 2012;13:15
74. Smolders J, Hupperts R, Barkhof F, et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011;311(1-2):44-9
75. Grimaldi L, Barkhof FBeelke M, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2012;78(11):841
76. Stein MS, Liu Y, Gray OM, et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011;77(17):1611-18
77. von Geldern G, Mowry EM. The influence of nutritional factors on the prognosis of multiple sclerosis. Nat Rev Neurol 2012;8(12):678-89
78. Weinstock-Guttman B, Mehta BK, Ramanathan M, et al. Vitamin D and multiple sclerosis. Neurologist 2012;18(4):179-83
79. Soilu-Hanninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2012;83(5):565-71
80. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96(7):1911-30
81. Holmoy T, Kampman MT, Smolders J. Vitamin D in multiple sclerosis: implications for assessment and treatment. Expert Rev Neurother 2012;12(9):1101-12
82. Steffensen LH, Brustad M, Kampman MT. What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year? J Neurol 2013;26(1):182-8
83. Saltyte Benth J, Myhr KM, Loken-Amsrud KI, et al. Modelling and prediction of 25-hydroxyvitamin D levels in Norwegian relapsing-remitting multiple sclerosis patients. Neuroepidemiology 2012;39(2):84-93
84. Waschbisch A, Wenny I, Tallner A, et al. Physical activity in multiple sclerosis: a comparative study of vitamin D, brain-derived neurotrophic factor and regulatory T cell populations. Eur Neurol 2012;68(2):122-8
85. Knippenberg S, Bol Y, Damoiseaux J, et al. Vitamin D status in patients with MS is negatively correlated with depression, but not with fatigue. Acta Neurol Scand 2011;124(3):171-5
86. Kirbas A, Kirbas S, Anlar O, et al. Investigation of the relationship between vitamin D and bone mineral density in newly diagnosed multiple sclerosis. Acta Neurol Belg 2012;[Epub ahead of print]
87. Moen SM, Celius EG, Sandvik L, et al. Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study. PLoS One 2012;7(9):e45703
88. Fernandes de Abreu DA, Ibrahim EC, Boucraut J, et al. Severity of experimental autoimmune encephalomyelitis is unexpectedly reduced in mice born to vitamin D-deficient mothers. J Steroid Biochem Mol Biol 2010;121(1-2):250-3
89. Fernandes de Abreu DA, Landel V, Barnett AG, et al. Prenatal vitamin d deficiency induces an early and more severe experimental autoimmune encephalomyelitis in the second generation. Int J Mol Sci 2012;13(9):10911-19
90. Disanto G, Handel AE, Morahan JM, et al. Comment on "Epigenetic reduction in invariant NKT cells following in utero vitamin D deficiency in mice". J Immunol 2011;186(7):3803-4